348 related articles for article (PubMed ID: 17525906)
1. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03.
Escherich G; Zimmermann M; Janka-Schaub G;
Pediatr Blood Cancer; 2013 Feb; 60(2):254-7. PubMed ID: 22948968
[TBL] [Abstract][Full Text] [Related]
3. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
5. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
6. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
7. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
[TBL] [Abstract][Full Text] [Related]
8. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
[TBL] [Abstract][Full Text] [Related]
10. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
[TBL] [Abstract][Full Text] [Related]
11. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic hypoglycemia in children receiving oral purine analogues for treatment of childhood acute lymphoblastic leukemia.
Ziino O; Russo D; Orlando MA; Benigno V; Locatelli F; Aricò M
Med Pediatr Oncol; 2002 Jul; 39(1):32-4. PubMed ID: 12116076
[TBL] [Abstract][Full Text] [Related]
13. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
Hunault-Berger M; Milpied N; Bernard M; Jouet JP; Delain M; Desablens B; Sadoun A; Guilhot F; Casassus P; Ifrah N
Leukemia; 2001 Jun; 15(6):898-902. PubMed ID: 11417474
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study.
Cuttner J; Mick R; Budman DR; Mayer RJ; Lee EJ; Henderson ES; Weiss RB; Paciucci PA; Sobol R; Davey F
Leukemia; 1991 May; 5(5):425-31. PubMed ID: 2033963
[TBL] [Abstract][Full Text] [Related]
15. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract][Full Text] [Related]
16. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
[TBL] [Abstract][Full Text] [Related]
18. Intravenous 6-mercaptopurine decreases salvage after relapse in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group study CCG 1922.
Tolar J; Bostrom BC; La MK; Sather HN
Pediatr Blood Cancer; 2005 Jul; 45(1):5-9. PubMed ID: 15481062
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
20. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
